Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy-Reference-Cited by-同舟云学术

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy

Published:2008-03-13 Issue:10 Volume:112 Page:2228-2232
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Coleman Morton,Martin Peter,Ruan Jia,Furman Richard,Niesvizky Ruben,Elstrom Rebecca,George Patricia,Kaufman Thomas P.,Leonard John P.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. Chemotherapy of the non-Hodgkins lymphoma;Pasmantier;Med Clin North Am.,1976

2. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma;Coleman;Semin Hematol.,1988

3. Chemotherapy for large cell lymphoma: a status update;Yi;Semin Oncol.,1990

4. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkins lymphoma;Fisher;N Engl J Med.,1998

5. Overview of non-Hodgkins lymphoma and biology, staging, treatment;Fisher;Semin Oncol.,2003

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

2. Macrophages and angiogenesis in human lymphomas;Clinical and Experimental Medicine;2024-01-29

3. Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial;Chinese Medical Journal;2023-10-13

4. All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma;Frontiers in Oncology;2023-05-26

5. Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma;Asian Journal of Surgery;2023-05